Cases & Deals

Franklin Templeton invests in Edge Therapeutics

Clients Franklin Templeton

Jones Day advised Franklin Templeton in connection with its purchase of Series C-2 Convertible Preferred Stock in a private placement by Edge Therapeutics, Inc., a clinical-stage biotechnology company that discovers, develops, and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions.